The Role of Liquid Biopsies in Surgical Pathology: Current Applications and Future Directions

Tuatini Whittemore^*
*Correspondence: Tuatini Whittemore, Department of Surgical Pathology, University of Pennsylvania, Philadelphia, PA 19104, USA, Email:

Keywords

Surgical pathology • Liquid biopsies • Diagnostic medicine

Introduction

Surgical pathology traditionally relies on tissue biopsies to diagnose and manage diseases, particularly cancers. While effective, these methods can be invasive, time-consuming and occasionally insufficient for comprehensive analysis. Liquid biopsies, which analyze biomarkers in bodily fluids like blood, present a less invasive approach that could complement or, in some cases, replace traditional tissue biopsies. This paper examines the role of liquid biopsies in surgical pathology, focusing on their current applications and potential future developments.

Literature Review

Liquid biopsies have emerged as a transformative tool in cancer diagnosis and monitoring, offering a non-invasive method to detect and analyze cancer-related biomarkers in bodily fluids, most commonly blood. This approach provides real-time insights into tumor dynamics, which are critical for effective management and treatment of cancer. This section delves into the applications of liquid biopsies in cancer diagnosis and monitoring, highlighting their current use, benefits and challenges.

Cancer diagnosis

• One of the primary applications of liquid biopsies in cancer diagnosis is the detection of genetic mutations. Tumor cells release DNA fragments into the bloodstream, which can be analyzed to identify mutations associated with specific cancers. For instance, in non-small cell lung cancer (NSCLC), mutations in the EGFR gene are common. Liquid biopsies can detect these mutations, helping to confirm a diagnosis and tailor targeted therapies.
• Liquid biopsies can also identify other tumor-specific biomarkers, such as methylation patterns or specific proteins. These biomarkers can be indicative of the presence of cancer and provide valuable diagnostic information. For example, the presence of the biomarker CA19-9 in the blood is often associated with pancreatic cancer.
• Liquid biopsies hold promise for early cancer detection, which is crucial for improving prognosis and survival rates. By identifying cancer-related biomarkers at an early stage, liquid biopsies could potentially enable earlier intervention. This is particularly valuable in cancers that are difficult to screen for, such as ovarian and pancreatic cancers [1].

Cancer monitoring

• Liquid biopsies are instrumental in assessing how well a patient is responding to treatment. By analyzing changes in the levels of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), clinicians can gauge the effectiveness of therapies. A decrease in ctDNA levels, for instance, often indicates that a treatment is working, while stable or increasing levels may suggest resistance or disease progression.
• After initial treatment, liquid biopsies can be used to detect minimal residual disease (MRD), which refers to the small number of cancer cells that may remain in the body and potentially lead to relapse. MRD detection through liquid biopsies can provide crucial information about the likelihood of recurrence and guide decisions regarding further treatment.
• Liquid biopsies enable ongoing monitoring for cancer relapse or disease progression. Regular testing can help detect changes in biomarker levels that may indicate the return of cancer before clinical symptoms arise. This proactive approach allows for timely adjustments in treatment, potentially improving outcomes [2].

Benefits of liquid biopsies in cancer diagnosis and monitoring

• Liquid biopsies offer a significant advantage over traditional tissue biopsies due to their non-invasive nature. The ability to obtain diagnostic information from a simple blood draw minimizes patient discomfort and risk.
• The dynamic nature of liquid biopsies allows for real-time monitoring of disease and treatment response. This ongoing feedback is crucial for personalized treatment planning and adjustment.
• Liquid biopsies can provide a comprehensive assessment of tumor biology, including genetic mutations, copy number variations and other biomarkers. This broad analysis helps in understanding the tumor's characteristics and tailoring treatment strategies accordingly [3].

Discussion

Challenges and limitations

• One of the main challenges of liquid biopsies is ensuring adequate sensitivity and specificity. Not all cancers shed sufficient amounts of ctDNA or CTCs, which can lead to false-negative results. Additionally, distinguishing between cancer-related and benign biomarkers can be challenging.
• The methodologies used in liquid biopsies need further standardization and validation. Variability in testing techniques and interpretation can affect clinical outcomes and hinder widespread adoption.
• The cost of liquid biopsies can be prohibitive and their availability may be limited by geographic and economic factors. Reducing costs and improving accessibility are crucial for broader implementation.

Future directions

• Continued advancements in sequencing technologies, such as next-generation sequencing (NGS) and improvements in biomarker detection are expected to enhance the accuracy and utility of liquid biopsies. Developing more sensitive assays for detecting lower quantities of ctDNA and CTCs is a key area of ongoing research.
• For liquid biopsies to become a standard component of cancer diagnosis and monitoring, they must be integrated into clinical practice through regulatory approval and clinical guidelines. Research focusing on their clinical utility in various cancers and stages of disease will be vital for this integration [4].
• While current applications of liquid biopsies are primarily in oncology, future research may expand their use to other areas, such as genetic disorders and infectious diseases, broadening their impact on medical diagnostics.
• Liquid biopsies facilitate personalized medicine by identifying specific genetic alterations that inform targeted treatment options. They also enable real-time monitoring of treatment efficacy and resistance. This is particularly valuable in managing cancers like breast cancer, where resistance to hormone therapy can be detected early through changes in ctDNA levels.

Minimal Residual Disease (MRD) refers to the small number of cancer cells that may remain in a patient's body after treatment and can lead to relapse. Detecting MRD is crucial in cancer management as it provides insights into the effectiveness of therapy and the risk of disease recurrence. Traditional methods for MRD detection, such as bone marrow biopsies or imaging, can be invasive or limited in sensitivity. Liquid biopsies offer a less invasive alternative for MRD detection, analyzing biomarkers in bodily fluids, particularly blood. This section explores the role of liquid biopsies in MRD detection, including current techniques, benefits and challenges [5].

Current techniques for MRD detection using liquid biopsies

• ctDNA is a key biomarker for MRD detection. Tumor cells shed DNA fragments into the bloodstream and these can be analyzed to identify residual cancer cells. The sensitivity of ctDNA analysis has improved with advancements in sequencing technologies. Methods like digital droplet PCR (ddPCR) and next-generation sequencing (NGS) are used to quantify ctDNA levels and detect specific mutations associated with the tumor. A decrease in ctDNA levels post-treatment can indicate a response to therapy, while persistently elevated levels may suggest residual disease.
• CTCs are viable tumor cells that circulate in the bloodstream. Techniques like immunomagnetic separation and microfluidic devices can capture and analyze CTCs. The presence and quantity of CTCs in the blood can provide information about MRD. While less commonly used than ctDNA, CTCs can be valuable in cases where ctDNA levels are low or undetectable.
• Cell-free RNA, including microRNAs and long non-coding RNAs, can also be used for MRD detection. These RNA molecules can be isolated from blood samples and analyzed for expression profiles associated with residual disease. Research into cfRNA is ongoing and it shows potential for detecting MRD, particularly in hematologic malignancies.

Benefits of liquid biopsies for MRD detection

• Liquid biopsies offer a non-invasive method for MRD detection compared to traditional procedures like bone marrow biopsies. This reduces patient discomfort and risk, making regular monitoring more feasible.
• Liquid biopsies can detect low levels of residual disease with high sensitivity, enabling earlier detection of potential relapse. Early detection of MRD can lead to timely interventions, improving patient outcomes.
• The ability to perform regular liquid biopsy tests allows for real-time monitoring of disease status. This continuous assessment helps in making informed decisions about ongoing treatment and potential adjustments.

Challenges and limitations

• While liquid biopsies are sensitive, they may not detect MRD in all cases. Variability in the amount of ctDNA or CTCs released into the bloodstream can affect detection. Ensuring high sensitivity and specificity is crucial for accurate MRD detection.
• There is a need for standardization and validation of liquid biopsy techniques for MRD detection. Differences in methodology and interpretation can impact clinical outcomes. Consensus on standardized protocols is needed to ensure consistent and reliable results.
• Interpreting MRD results from liquid biopsies can be challenging. Elevated ctDNA or CTC levels do not always correlate with clinical relapse and false positives or negatives can occur. Understanding the clinical context and integrating liquid biopsy results with other diagnostic information is essential for accurate assessment.
• The cost of liquid biopsy technologies can be high and their availability may be limited by geographic and economic factors. Reducing costs and increasing accessibility are important for broader implementation [6].

Future directions

• Continued advancements in sequencing technologies and biomarker detection methods are expected to enhance the sensitivity and accuracy of MRD detection. Research into novel biomarkers and improved assays will further refine liquid biopsy techniques.
• For liquid biopsies to become a standard tool for MRD detection, they must be integrated into clinical practice through regulatory approval and established guidelines. Research into their utility across different cancers and stages of disease will support this integration.
• Combining liquid biopsies with other diagnostic methods, such as imaging or tissue biopsies, may improve the overall accuracy and utility of MRD detection. Multimodal approaches could provide a more comprehensive assessment of disease status.
• Personalized monitoring strategies using liquid biopsies could optimize patient management. Tailoring MRD detection and monitoring based on individual patient characteristics and tumor profiles will enhance the effectiveness of treatment strategies

Advantages of liquid biopsies

• The primary advantage of liquid biopsies is their non-invasive nature. Unlike traditional biopsies, which require surgical procedures, liquid biopsies involve a simple blood draw, reducing patient discomfort and risk.
• Liquid biopsies enable continuous monitoring of disease progression and treatment response. This real-time data allows for timely adjustments in treatment strategies.
• Early detection of relapse or disease progression through liquid biopsies can lead to prompt intervention, potentially improving patient outcomes.

Limitations and challenges

• While liquid biopsies offer many benefits, their sensitivity and specificity can vary. Not all cancers shed detectable amounts of ctDNA or CTCs, which can lead to false negatives or inadequate results.
• The methodologies and technologies used in liquid biopsies need further standardization and validation. Variability in techniques and interpretations can affect clinical outcomes and the reliability of results.
• Currently, the cost of liquid biopsies can be high and their accessibility may be limited by geographic and economic factors. Addressing these issues is crucial for broader adoption.

Future directions

• Continued advancements in sequencing technologies, such as next-generation sequencing (NGS) and improvements in biomarker detection will enhance the accuracy and utility of liquid biopsies. Developing more sensitive assays to detect lower quantities of ctDNA and CTCs is a key area of research.
• For liquid biopsies to become a standard component of surgical pathology, they must be integrated into clinical practice through regulatory approval and guidelines. Research focusing on their clinical utility in various cancers and diseases will be vital for this integration.
• Efforts to reduce the cost of liquid biopsies and improve their accessibility will be essential. This includes developing more cost-effective testing methods and increasing insurance coverage.
• Future research should explore the role of liquid biopsies in personalized medicine beyond oncology, including in genetic disorders and infectious diseases. This will help to expand their applications and improve patient management across different conditions.

Conclusion

Liquid biopsies represent a significant advancement in surgical pathology, offering a less invasive and potentially more comprehensive approach to disease diagnosis and management. While there are challenges to overcome, including improving sensitivity and reducing costs, the future of liquid biopsies holds great promise. As technology advances and research progresses, liquid biopsies are likely to become an integral part of surgical pathology, enhancing patient care and outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Finn, Roisin, Mario Ganau, Michael D. Jenkinson and Puneet Plaha. "COVID-legal study: Neurosurgeon experience in Britain during the first phase of the COVID-19 pandemic–medico-legal considerations."Br J Neurosurg 35 (2021): 547-550.

   Google Scholar, Crossref, Indexed at

2. Fontanella, Marco M., Lucio De Maria, Luca Zanin and Giorgio Saraceno, et al. "Neurosurgical practice during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic: A worldwide survey."World Neurosurg 139 (2020): e818-e826.

   Google Scholar, Crossref, Indexed at

3. Sarnicola, Caterina, Asim V. Farooq and Kathryn Colby. "Fuchs endothelial corneal dystrophy: Update on pathogenesis and future directions."Eye Contact Lens45 (2019): 1-10.

   Google Scholar, Crossref, Indexed at

4. Matthaei, Mario, Agathe Hribek, Thomas Clahsen and Björn Bachmann, et al. "Fuchs endothelial corneal dystrophy: Clinical, genetic, pathophysiologic and therapeutic aspects."Annu Rev Vis Sci5 (2019): 151-175.

   Google Scholar, Crossref, Indexed at

5. Gonçalves, Eliana Domingues, Mauro Campos, Fabiana Paris and José Alvaro Pereira Gomes, et al. "Bullous keratopathy: Etiopathogenesis and treatment."Arq Bras Oftalmo 71 (2008): 61-64.

   Google Scholar, Crossref

6. Pricopie, Stefan, Sanziana Istrate, Liliana Voinea and Costin Leasu, et al. "Pseudophakic bullous keratopathy."Rom J Ophthalmol 61 (2017): 90.

   Google Scholar, Crossref, Indexed at